The Use of the Mannitol Test As an Outcome Measure in Asthma Intervention Studies: a Review and Practical Recommendations

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2021 Nov 8

PMID 34743708

Authors

Asger Sverrild

Joanna Leadbetter

Celeste Porsbjerg

Affiliations

Soon will be listed here.

Abstract

Background: The mannitol test is an indirect bronchial challenge test widely used in diagnosing asthma. Response to the mannitol test correlates with the level of eosinophilic and mast cell airway inflammation, and a positive mannitol test is highly predictive of a response to anti-inflammatory treatment with inhaled corticosteroids. The response to mannitol is a physiological biomarker that may, therefore, be used to assess the response to other anti-inflammatory treatments and may be of particular interest in early phase studies that require surrogate markers to predict a clinical response. The main objectives of this review were to assess the practical aspects of using mannitol as an endpoint in clinical trials and provide the clinical researcher and respiratory physician with recommendations when designing early clinical trials.

Methods: The aim of this review was to summarise previous uses of the mannitol test as an outcome measure in clinical intervention studies. The PubMed database was searched using a combination of MeSH and keywords. Eligible studies included intervention or repeatability studies using the standard mannitol test, at multiple timepoints, reporting the use of PD as a measure, and published in English.

Results: Of the 193 papers identified, 12 studies met the inclusion criteria and data from these are discussed in detail. Data on the mode of action, correlation with airway inflammation, its diagnostic properties, and repeatability have been summarised, and suggestions for the reporting of test results provided. Worked examples of power calculations for dimensioning study populations are presented for different types of study designs. Finally, interpretation and reporting of the change in the response to the mannitol test are discussed.

Conclusions: The mechanistic and practical features of the mannitol test make it a useful marker of disease, not only in clinical diagnoses, but also as an outcome measure in intervention trials. Measuring airway hyperresponsiveness to mannitol provides a novel and reproducible test for assessing efficacy in intervention trials, and importantly, utilises a test that links directly to underlying drivers of disease.

Citing Articles

Evaluation of bronchial hyperresponsiveness in asthmatic paediatric patients using mannitol challenge test - Impacts of body mass index.

Leung S, Tsang H, Chan J, Kui O, Zeng P, Cheung Y Ann Med. 2025; 57(1):2468262.

PMID: 39977003 PMC: 11843638. DOI: 10.1080/07853890.2025.2468262.

References

Agusti A, Bafadhel M, Beasley R, Bel E, Faner R, Gibson P . Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017; 50(4). DOI: 10.1183/13993003.01655-2017. View

Kernen P, Steveling-Klein E, Saccilotto R, Raatz H, Briel M, Koller M . The sensitivity and specificity of the mannitol bronchial challenge test to identify asthma in different populations: a systematic review. Swiss Med Wkly. 2019; 149:w20100. DOI: 10.4414/smw.2019.20100. View

Porsbjerg C, Sverrild A, Backer V . Combining the Mannitol Test and FeNO in the Assessment of Poorly Controlled Asthma. J Allergy Clin Immunol Pract. 2015; 3(4):553-9. DOI: 10.1016/j.jaip.2015.02.005. View

Clearie K, McKinlay L, Williamson P, Lipworth B . Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke. Chest. 2011; 141(2):330-338. DOI: 10.1378/chest.11-0392. View

Anderson S . Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2 Suppl):25S-30S. DOI: 10.1378/chest.10-0116. View

Brannan J, Anderson S, Perry C, Freed-Martens R, Lassig A, Charlton B . The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res. 2005; 6:144. PMC: 1326200. DOI: 10.1186/1465-9921-6-144. View

Porsbjerg C, Brannan J, Anderson S, Backer V . Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin Exp Allergy. 2007; 38(1):43-50. DOI: 10.1111/j.1365-2222.2007.02878.x. View

Backer V, Sverrild A, Ulrik C, Bodtger U, Seersholm N, Porsbjerg C . Diagnostic work-up in patients with possible asthma referred to a university hospital. Eur Clin Respir J. 2015; 2. PMC: 4629726. DOI: 10.3402/ecrj.v2.27768. View

Sverrild A, Porsbjerg C, Backer V . The use of inhaled mannitol in the diagnosis and management of asthma. Expert Opin Pharmacother. 2011; 13(1):115-23. DOI: 10.1517/14656566.2012.638917. View

10.

Brannan J, Bood J, Alkhabaz A, Balgoma D, Otis J, Delin I . The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma. Chest. 2014; 147(2):397-405. PMC: 4314816. DOI: 10.1378/chest.14-1214. View

11.

Sverrild A, Bergqvist A, Baines K, Porsbjerg C, Andersson C, Thomsen S . Airway responsiveness to mannitol in asthma is associated with chymase-positive mast cells and eosinophilic airway inflammation. Clin Exp Allergy. 2015; 46(2):288-97. DOI: 10.1111/cea.12609. View

12.

Toennesen L, Meteran H, Hostrup M, Geiker N, Jensen C, Porsbjerg C . Effects of Exercise and Diet in Nonobese Asthma Patients-A Randomized Controlled Trial. J Allergy Clin Immunol Pract. 2017; 6(3):803-811. DOI: 10.1016/j.jaip.2017.09.028. View

13.

Kersten E, Driessen J, Duiverman E, Thio B . The effect of stepping down combination therapy on airway hyperresponsiveness to mannitol. Respir Med. 2010; 105(5):691-7. DOI: 10.1016/j.rmed.2010.11.008. View

14.

Koskela H, Hyvarinen L, Brannan J, Chan H, Anderson S . Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest. 2003; 124(4):1341-9. DOI: 10.1378/chest.124.4.1341. View

15.

Udesen P, Westergaard C, Porsbjerg C, Backer V . Stability of FeNO and airway hyperresponsiveness to mannitol in untreated asthmatics. J Asthma. 2016; 54(5):530-536. DOI: 10.1080/02770903.2016.1238928. View

16.

Baraket M, Oliver B, Burgess J, Lim S, King G, Black J . Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study. Respir Res. 2012; 13:11. PMC: 3296667. DOI: 10.1186/1465-9921-13-11. View

17.

Pavord I, Holliday M, Reddel H, Braithwaite I, Ebmeier S, Hancox R . Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med. 2020; 8(7):671-680. DOI: 10.1016/S2213-2600(20)30053-9. View

18.

Julious S . Sample sizes for clinical trials with normal data. Stat Med. 2004; 23(12):1921-86. DOI: 10.1002/sim.1783. View

19.

Anderson W, Short P, Williamson P, Lipworth B . Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest. 2013; 142(6):1553-1561. DOI: 10.1378/chest.12-1310. View

20.

Brannan J, Anderson S, GOMES K, King G, Chan H, Seale J . Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med. 2001; 163(6):1420-5. DOI: 10.1164/ajrccm.163.6.2006019. View